📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. (2024)

First Author: Cope AP

Attributed to: Study into the potentially therapeutic immunomodulatory effects of gp120 in autoimmune rheumatic disease funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(23)02649-1

PubMed Identifier: 38364839

Publication URI: http://europepmc.org/abstract/MED/38364839

Type: Journal Article/Review

Volume: 403

Parent Publication: Lancet (London, England)

Issue: 10429

ISSN: 0140-6736